To the Editor I read with great interest the updated analysis of the SONIA trial by Wortelboer et al, which demonstrated that first-line use of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) did not improve overall survival (OS) compared with second-line use in hormone receptor–positive advanced breast cancer. This trial provides pivotal data challenging the paradigm of moving targeted therapies to earlier courses.
Классификация: Наука| # | Наименование новости | Тональность | Информативность | дата |
|---|---|---|---|---|
| 1 | Survival in the SONIA Trial | 0 | 0 | 18-06-2026 |
| 2 | Survival in the SONIA Trial—Reply | 0 | 0 | 18-06-2026 |
| 3 | Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer | 0 | 0 | 18-06-2026 |
| 4 | Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy | 0 | 0 | 18-06-2026 |
| 5 | Скворцова заявила, что рост показателя общей смертности от рака удалось стабилизировать | 0 | 0 | 25-09-2019 |
| 6 | Exercise may help protect older adults against cancer | 0 | 0 | 17-06-2026 |
| 7 | Специалисты не выявили нарушений при проверке оборудования в онкодиспансере Воронежа | 0 | 0 | 22-07-2019 |
| 8 | Error in Open Access License | 0 | 0 | 18-06-2026 |
| 9 | This GLP-1 drug may be best for weight loss | 0 | 0 | 15-06-2026 |
| 10 | Team finds protein that could help failing hearts recover | 0 | 0 | 31-05-2026 |
